Antiva Biosciences
PrivateLast Round
Series E
Apr 27, 2023
Total Funding Raised
$139.4M
Company Overview
Antiva Biosciences operates in Healthcare & Life Sciences and is based in Redwood City, California. Its latest recorded funding round was a Series E round in April 2023.
Antiva Biosciences is a biotechnology company that develops small molecule antivirals aimed at enhancing health outcomes for patients affected by HPV and other viral infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antiva Biosciences Comparables
Compare Antiva Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Frantz Viral Therapeutics | 82% | |
| Amplexd Therapeutics | 76% | |
| Asieris Pharmaceuticals | 73% |
For institutional investors. Book with your work email.
Antiva Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Apr 27, 2023 | ||||
| Series D | Nov 2, 2021 | ||||
| Series C Extension | Jul 10, 2018 | ||||
| Series C | Mar 28, 2017 | ||||
| Series B | Aug 6, 2015 | ||||
Series A | Jul 1, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Antiva Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sirona Capital | Series C Extension, Series D |
| Brace Pharma Capital | Series C, Series C Extension, Series D |
| GV | Series E, Series D |
| Hillhouse Investment | Series C Extension |
| Gaingels | Series D |
| Avestria Ventures | Series D |
| MPM BioImpact | Series E |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 70% MoM.
- May 15, 2026
Monthly visitors grew 530% MoM, reaching 1.8K.
For institutional investors. Book with your work email.
Antiva Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Antiva Biosciences's valuation, stock price, and market status.
Is Antiva Biosciences a public or private company?
Antiva Biosciences is a private company.
What is the current stock price of Antiva Biosciences?
Antiva Biosciences is a private company, so its shares have no public market price. Caplight tracks Antiva Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Antiva Biosciences worth (valuation)?
Valuation information for Antiva Biosciences is not publicly available.
Can I buy Antiva Biosciences stock?
Antiva Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Antiva Biosciences's last funding round?
Antiva Biosciences's most recent funding round was Series E on April 27, 2023.
Who are the main investors in Antiva Biosciences?
Key investors in Antiva Biosciences include Brace Pharma Capital, GV, Hillhouse Investment, MPM BioImpact, Canaan Partners.
Will Antiva Biosciences IPO soon?
No public IPO plans have been announced for Antiva Biosciences.
How can I track Antiva Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Antiva Biosciences's shares on secondary markets.